Anne M Muehe1, Dan Feng1, Rie von Eyben2, Sandra Luna-Fineman3, Michael P Link3, Travis Muthig4, Amy E Huddleston5, Edward A Neuwelt5, Heike E Daldrup-Link1. 1. Department of Radiology, Molecular Imaging Program at Stanford (MIPS) and Lucile Packard Children's Hospital, Stanford University, Stanford, CA, USA. 2. Department of Radiation Oncology, Stanford University, Stanford, CA, USA. 3. Department of Pediatrics, Section of Pediatric Hematology and Oncology, Stanford University, Stanford, CA, USA. 4. University of South Carolina School of Medicine, Columbia, SC, USA. 5. Departments of Neurology and Neurosurgery, Oregon Health & Science University, Portland, OR, USA, Portland Veterans Affairs Medical Center, Portland, OR, USA.
Abstract
OBJECTIVE: The aim of this study was to assess the safety profile of ferumoxytol as an intravenous magnetic resonance imaging contrast agent in children. MATERIALS AND METHODS: We prospectively evaluated the safety of ferumoxytol administrations as an "off-label" contrast agent for magnetic resonance imaging in nonrandomized phase 4 clinical trials at 2 centers. From September 2009 to February 2015, 49 pediatric patients (21 female and 28 male, 5-18 years) and 19 young adults (8 female and 11 male, 18-25 years) were reported under an investigator-initiated investigational new drug investigation with institutional review board approval, in health insurance portability and accountability act compliance, and after written informed consent of the child's legal representative or the competent adult patient was obtained. Patients received either a single dose (5 mg Fe/kg) or up to 4 doses of ferumoxytol (0.7-4 mg Fe/kg) intravenously, which were approximately equivalent to one third of the dose for anemia treatment. We monitored vital signs and adverse events directly for up to 1 hour after injection. In addition, we examined weekly vitals, hematologic, renal, and liver serum panels for 1 month after injection in over 20 pediatric patients. At fixed time points before and after ferumoxytol injection, data were evaluated for significant differences by a repeated measures linear mixed model. RESULTS: Four mild adverse events, thought to be related to ferumoxytol, were observed within 1 hour of 85 ferumoxytol injections: 2 episodes of mild hypotension and 1 case of nausea in 65 injections in pediatric patients without related clinical symptoms. One young adult patient developed warmness and erythema at the injection site. All adverse events were self-resolving. No spontaneous serious adverse events were reported. At a dose of 5 mg Fe/kg or lower, intravenous ferumoxytol injection had no clinical relevance or statistically significant effect (P > 0.05) on vital signs, hematological parameters, kidney function, or liver enzymes within 1 month of the injection. CONCLUSIONS: Ferumoxytol was overall well tolerated among 49 pediatric and 19 young adult patients experiencing various tumors or kidney transplants without major adverse events or signs of hematologic and kidney impairment or liver toxicity. Larger studies are needed to determine the incidence of anaphylactic reactions.
OBJECTIVE: The aim of this study was to assess the safety profile of ferumoxytol as an intravenous magnetic resonance imaging contrast agent in children. MATERIALS AND METHODS: We prospectively evaluated the safety of ferumoxytol administrations as an "off-label" contrast agent for magnetic resonance imaging in nonrandomized phase 4 clinical trials at 2 centers. From September 2009 to February 2015, 49 pediatricpatients (21 female and 28 male, 5-18 years) and 19 young adults (8 female and 11 male, 18-25 years) were reported under an investigator-initiated investigational new drug investigation with institutional review board approval, in health insurance portability and accountability act compliance, and after written informed consent of the child's legal representative or the competent adult patient was obtained. Patients received either a single dose (5 mg Fe/kg) or up to 4 doses of ferumoxytol (0.7-4 mg Fe/kg) intravenously, which were approximately equivalent to one third of the dose for anemia treatment. We monitored vital signs and adverse events directly for up to 1 hour after injection. In addition, we examined weekly vitals, hematologic, renal, and liver serum panels for 1 month after injection in over 20 pediatric patients. At fixed time points before and after ferumoxytol injection, data were evaluated for significant differences by a repeated measures linear mixed model. RESULTS: Four mild adverse events, thought to be related to ferumoxytol, were observed within 1 hour of 85 ferumoxytol injections: 2 episodes of mild hypotension and 1 case of nausea in 65 injections in pediatric patients without related clinical symptoms. One young adult patient developed warmness and erythema at the injection site. All adverse events were self-resolving. No spontaneous serious adverse events were reported. At a dose of 5 mg Fe/kg or lower, intravenous ferumoxytol injection had no clinical relevance or statistically significant effect (P > 0.05) on vital signs, hematological parameters, kidney function, or liver enzymes within 1 month of the injection. CONCLUSIONS:Ferumoxytol was overall well tolerated among 49 pediatric and 19 young adult patients experiencing various tumors or kidney transplants without major adverse events or signs of hematologic and kidney impairment or liver toxicity. Larger studies are needed to determine the incidence of anaphylactic reactions.
Authors: Eric M Thompson; Daniel J Guillaume; Edit Dósa; Xin Li; Kellie J Nazemi; Seymur Gahramanov; Bronwyn E Hamilton; Edward A Neuwelt Journal: J Neurooncol Date: 2012-04-19 Impact factor: 4.130
Authors: Jonathan R Dillman; James H Ellis; Richard H Cohan; Peter J Strouse; Sophia C Jan Journal: AJR Am J Roentgenol Date: 2007-12 Impact factor: 3.959
Authors: Bruce S Spinowitz; Annamaria T Kausz; Jovanna Baptista; Sylvia D Noble; Renuka Sothinathan; Marializa V Bernardo; Louis Brenner; Brian J G Pereira Journal: J Am Soc Nephrol Date: 2008-06-04 Impact factor: 10.121
Authors: Eric M Gale; Peter Caravan; Anil G Rao; Robert J McDonald; Matthew Winfeld; Robert J Fleck; Michael S Gee Journal: Pediatr Radiol Date: 2017-04-13
Authors: Andrea Horváth; Csanad G Varallyay; Daniel Schwartz; Gerda B Toth; Joao P Netto; Ramon Barajas; Péter Várallyay; László Szidonya; Jenny Firkins; Emily Youngers; Rongwei Fu; Prakash Ambady; Péter Bogner; Edward A Neuwelt Journal: Magn Reson Med Date: 2017-12-04 Impact factor: 4.668
Authors: Klara Kirschbaum; Jana K Sonner; Matthias W Zeller; Katrin Deumelandt; Julia Bode; Rakesh Sharma; Thomas Krüwel; Manuel Fischer; Angelika Hoffmann; Milene Costa da Silva; Martina U Muckenthaler; Wolfgang Wick; Björn Tews; John W Chen; Sabine Heiland; Martin Bendszus; Michael Platten; Michael O Breckwoldt Journal: Proc Natl Acad Sci U S A Date: 2016-10-31 Impact factor: 11.205
Authors: Gerda B Toth; Csanad G Varallyay; Andrea Horvath; Mustafa R Bashir; Peter L Choyke; Heike E Daldrup-Link; Edit Dosa; John Paul Finn; Seymur Gahramanov; Mukesh Harisinghani; Iain Macdougall; Alexander Neuwelt; Shreyas S Vasanawala; Prakash Ambady; Ramon Barajas; Justin S Cetas; Jeremy Ciporen; Thomas J DeLoughery; Nancy D Doolittle; Rongwei Fu; John Grinstead; Alexander R Guimaraes; Bronwyn E Hamilton; Xin Li; Heather L McConnell; Leslie L Muldoon; Gary Nesbit; Joao P Netto; David Petterson; William D Rooney; Daniel Schwartz; Laszlo Szidonya; Edward A Neuwelt Journal: Kidney Int Date: 2017-04-20 Impact factor: 10.612
Authors: Lillian M Lai; Joseph Y Cheng; Marcus T Alley; Tao Zhang; Michael Lustig; Shreyas S Vasanawala Journal: J Magn Reson Imaging Date: 2016-09-28 Impact factor: 4.813